About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, January 26th, 2018

The QualityStocks
Daily Stock List


Helix TCS, Inc. (HLIX)

Market Exclusive, GreenMarketReport, The Stock Rover, The Daly Marijuana Observer, Marketwired, Simply Wall St, Business Insider, Stock Daily Review, and The Street reported on Helix TCS, Inc. (HLIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Helix TCS, Inc. is a provider of integrated operating environment solutions for the legal cannabis Industry. The Company has acquired Cannabase, which is the oldest and largest wholesale platform in the cannabis industry. Helix TCS’ mission is to provide clients with the most powerful and inventive integrated operating environments in the market. This is to help clients better manage and lessen risk while they concentrate on their core business. OTCQB-listed, Helix TCS is based in Greenwood Village, Colorado.

The Company’s team consists of former military, law enforcement, and technology professionals. These have significant experience in security and law enforcement, intelligence, technology design and development, partner relations, data aggregation, venture capital, private equity, risk-management, banking, and finance.

Helix TCS’ services include Technology, Compliance, and Security. It offers a technology platform that allows clients to manage inventory and supply costs by way of Cannabase.

Regarding Compliance, the Company has a wide range of compliance services for companies in the Cannabis Industry. This safeguards clients’ ability to operate while increasing their access to services.

Concerning Security, Helix TCS offers Transport, Armed and Unarmed Guarding, Training, Investigation, as well as Special Services. Security is the Company’s flagship service offering.

In June of 2017, Helix TCS announced its acquisition of Security Grade Protective Services, Ltd.  Security Grade now operates as a wholly-owned subsidiary of Helix TCS. Security Grade is a Denver, Colorado-headquartered security firm. It provides a range of custom, full-service security solutions to cannabis business customers.

Security Grade has a strong concentration on surveillance technology. This acquisition allows Helix TCS to continue to expand its family of operating solutions with a number of services. These services include Information Technology (IT) security, building fortification, private investigations, and advanced video surveillance programs and software.

Helix TCS reported Revenue that increased in Q3 2017 85 percent from the previous year Q3, to $1,129,746. This was propelled by a major increase in the Company’s number of clients and also a full quarter of revenue from its Security Grade acquisition.

Helix TCS, Inc. (HLIX), closed Friday's trading session at $2.15, up 1.90%, on 8,356 volume with 17 trades. The average volume for the last 60 days is 5,176 and the stock's 52-week low/high is $0.75/$13.00.

Chemistree Technology, Inc. (CHMJF)

OTC Markets, 4-Traders, WatchDog Stocks, Penny Stock Hub, Stockhouse, Dividend Investor, JetLife Penny Stocks, Investors Hangout, Wall Street Pennies, Investing News Alerts, OTC stock picks, and TradingView reported on Chemistree Technology, Inc. (CHMJF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Chemistree Technology, Inc. focuses on social media, branding, licensing, and marketing technology. The Company markets events, brands, and any other activities in the cannabis industry. Nonetheless, it will continue to identify other avenues for growth for social media marketing services, and brand marketing, product marketing, and more general services.

Chemistree Technology has its corporate headquarters in Vancouver, British Columbia. In September 2017, Chemistree Technology announced that its Common Shares were approved for trading on the OTCQB Venture Market in the U.S under the new trading symbol CHMJF, effective September 26, 2017.

Fundamentally, the Company has expertise in branding and digital marketing. It uses technology to connect consumers with brands.

At first, the Pacific Northwest is Chemistree Technology’s chief target geography. However, the expectation is that this will expand from British Columbia and Washington into Oregon, and eventually California.

Pertaining to Brand Development, the Company can take over the tangible elements of brand management. This includes the graphic design that determines the look and feel of a company. Chemistree can also manage all facets of how a brand is perceived in the market.

The Company specializes in social media. It develops and implements premier social media solutions for Cannabis brands based on their unique business objectives.

Chemistree Technology Management has recently toured a number of operations in the Los Angeles, California area. The purpose of these visits was to identify other areas into which Chemistree can expand and deploy capital and management’s considerable, collective expertise to build shareholder value.

Last week, Chemistree Technology announced that it was engaged by Elite Extracts of Vancouver  to assist them with their social media marketing and brand development as they prepare to launch their business.

Chief Operating Officer (COO), Mr. Jeremy Deichen, said, “I am happy to announce that Elite Extracts has chosen Chemistree to assist them with social media marketing as they continue to develop their business. Chemistree is providing Elite a full range of branding services including web design, packaging and graphic design work. We are looking forward to being part of their future success.”

Chemistree Technology, Inc. (CHMJF), closed Friday's trading session at $0.6837, up 14.14%, on 4,650 volume with 4 trades. The average volume for the last 60 days is 2,041 and the stock's 52-week low/high is $0.012/$0.7158.

alpha-En Corp. (ALPE)

Wall Street Mover and Real Pennies reported previously on alpha-En Corp. (ALPE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corp. is a clean technology business listed on the OTCQB. The Company focuses on enabling next generation battery technologies through developing and bringing to market high purity lithium metal and associated products produced in an environmentally sustainable manner. Its lithium metal is purer than what is now available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply. alpha-En has its corporate headquarters in Yonkers, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company has strategic research partnerships with Argonne National Laboratory, Princeton University, and the City University of New York. These partnerships are to advance commercialization and scale-up of production.

alpha-En enables next generation energy storage. The Company’s emphasis is on room temperature production of high purity lithium metal and associated products. alpha-En’s flexible disposition method can also streamline battery manufacturing leading to battery production cost benefits.

Its room temperature, proprietary patent pending process is mercury and chlorine free. This eliminates the use and release of toxic chemicals and expensive containment costs.

In addition, the room temperature process requires minimal electricity, and using Lithium Carbonate as feedstock lessens alpha-En`s raw material costs. The process is conducted at 20°-30°C.

In September 2017, alpha-En announced an award of $750,000 from the U.S. Department of Energy's Office of Technology Transition Technology Commercialization Fund (TCF). The Company and Argonne National Lab will advance alpha-En technology to produce lithium metal anodes for EV Batteries with the award from the DOE Technology Commercialization Fund. The funding will be used to commercialize Argonne's proprietary highly conductive solid-state electrolyte coating for alpha-En's lithium metal anodes.

Last month, alpha-En announced that it filed, by way of its subsidiary CLC, several patent applications that relate to and claim high purity lithium and associated products and the process of making same. This further strengthens the core Intellectual Property (IP) of alpha-En that has already filed manifold patents around its proprietary technology.

alpha-En Corp. (ALPE), closed Friday's trading session at $2.19, up 0.11%, on 763 volume with 68 trades. The average volume for the last 60 days is 4,535 and the stock's 52-week low/high is $1.16/$4.35.

Argentina Lithium & Energy Corp. (PNXLF)

Barchart, MarketWatch, Marketwired, and OTC Markets reported on Argentina Lithium & Energy Corp. (PNXLF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Argentina Lithium & Energy Corp. centers on the acquisition and exploration of natural resource properties in Argentina. The Company concentrates on acquiring high quality lithium projects in Argentina and advancing them towards production to meet the rising international demand from the battery sector. A natural resource enterprise, Argentina Lithium & Energy is headquartered in Vancouver, British Columbia. The Company has its Argentina Exploration Office in Mendoza, Argentina.

Argentina comprises a substantial portion of the Lithium Triangle. This is home to over half of the globe’s resources of lithium.

Argentina Lithium & Energy is a member of the Grosso Group. This is a resource management team, which pioneered the mineral exploration industry in Argentina. It has operated in the country since 1993. The Grosso Group leverages its wide-ranging network of local, regional, and worldwide industry contacts to support the exploration team in its search for quality resource opportunities.

Argentina Lithium & Energy has the option to earn a 100 percent interest in the Arizaro Lithium Brine Project. This includes 20,500 hectares in the central core of the Arizaro Salar, which is the largest in Argentina and the third largest in the Lithium Triangle. The geological environment at Arizaro includes volcanic rock outcrops and structural conditions similar to other salars in the Puna region where lithium and potash are found.

The central area of the Arizaro Salar is interpreted to have the geologic conditions to be the most prospective for quality brine resources. Additionally, the Arizaro Salar also benefits from a strategic location for infrastructure. This includes a railway that connects to the deep water port of Antofagasta, nearby advanced mining projects expected to bring major development of access routes and power, and also the availability of water for development.

Argentina Lithium & Energy reported in September 2017 that it initiated its first drilling and subsurface brine sampling program at the 20,500 hectare Arizaro Lithium Project on the Arizaro Salar in Salta Province.

This past November, Argentina Lithium & Energy announced that it acquired a 100 percent interest in, or has under application, mineral rights totaling 23,700 hectares encompassing the entire Incahuasi Salar and basin in Catamarca Province, Argentina. This salar is within the “Lithium Triangle” of Argentina and Chile. It has characteristics prospective for lithium-rich brines. Initial sampling of near-surface brines returned up to 409mg/L lithium. Geophysical surveying indicates the potential for lithium-rich brines at depth.

Furthermore, in November, Argentina Lithium & Energy announced that the first two drill holes at the Arizaro project encountered lithium-bearing brines below surface in the central area of the salar with values as high as 257 mg/l lithium. A significant brine aquifer has not yet been reached. However, modest volumes of significantly anomalous lithium-bearing brines were retrieved beginning at depths of between 15 and 356 meters.

Recently, Argentina Lithium & Energy expanded the property holdings at the Arizaro project by an additional 7,030 ha. Geophysical and seismic surveying is the next step before a Phase II drill program to test for deep brines.

Argentina Lithium & Energy Corp. (PNXLF), closed Friday's trading session at $0.3598, up 1.07%, on 26,450 volume with 28 trades. The average volume for the last 60 days is 57,282 and the stock's 52-week low/high is $0.0744/$0.479.

MRI Interventions, Inc. (MRIC)

Wall Street Resources, Real Pennies, and FeedBlitz reported earlier on MRI Interventions, Inc. (MRIC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. is a commercial stage medical device company. It develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain under direct, intra-procedural Magnetic Resonance Imaging, or MRI, guidance. Using a hospital's existing MRI suite, the design of its Food and Drug Administration (FDA)-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. Listed on the OTCQB, MRI Interventions has its headquarters in Irvine, California.

The Company’s emphasis is Magnetic Resonance Imaging (MRI)-Guided Neurosurgical procedures. The ClearPoint® system enables real-time MRI-guided navigation for a wide assortment of minimally-invasive neurosurgery procedures.

The platform is especially well-matched for facilitating drug delivery directly to brain tumors. The ClearPoint® system is the only navigation platform designed to allow real-time visualization during minimally-invasive neurosurgical procedures.

MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, regarding the ClearPoint® system. Furthermore, MRI Interventions is developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation.

ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software. The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.

Earlier this month, MRI Interventions announced the first brain tumor surgery in Minnesota performed utilizing the ClearPoint® Neuro Navigation System at the University of Minnesota Medical Center. University of Minnesota Health represents collaboration between University of Minnesota Physicians, Fairview Health Services, and University of Minnesota Medical Center.

This week, MRI Interventions commented on Voyager Therapeutics’ announcement of FDA clearance of its Investigational New Drug (IND) application for VY-AADC. This is Voyager’s gene therapy program targeting advanced Parkinson’s disease. Clearance of the IND permits Voyager Therapeutics to formally start clinical trial sites and commence screening patients for its pivotal Phase 2-3 program.

Wendelin Maners, Vice President of Marketing and Clinical Operations at MRI Interventions, said, “We are excited that FDA cleared this IND, allowing commencement of Voyager’s gene therapy pivotal program for advanced Parkinson’s disease. This represents an important milestone in our own pipeline of gene therapy and drug delivery trials utilizing the ClearPoint® Neuro Navigation system and SmartFlow® drug delivery cannulas as the premier targeting platform for direct deployment of biologics to precise regions within the brain.”

MRI Interventions, Inc. (MRIC), closed Friday's trading session at $2.70, up 5.88%, on 32,350 volume with 26 trades. The average volume for the last 60 days is 21,429 and the stock's 52-week low/high is $1.76/$7.40.

Biotricity, Inc. (BTCY)

SmallCap Network, Stock News Now, and SECFilings News reported previously on Biotricity, Inc. (BTCY), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Biotricity, Inc. is a medical diagnostic and consumer healthcare technology company listed on the OTC Markets Group’s OTCQB. The Company’s commitment is to deliver biometric remote monitoring solutions. Biotricity delivers these solutions to the medical and consumer markets. This includes diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity has its corporate off ice in Redwood City, California.

Biotricity’s vision is putting health management into the hands of the individual. It is working to support the self-management of critical and chronic conditions with the use of unique solutions to ease the growing burden on the healthcare system. Biotricity’s Research and Development (R&D) continues to center on the preventative healthcare market.

Biotricity has created two ECG monitoring devices. The design of these is to improve upon the tools and devices presently available in today’s market. For Physicians, the Company has its Bioflux. This is a medical technology solution for physicians to test and diagnose patients, and benefit from an innovative system, which provides ongoing active monitoring for up to 30 consecutive days.

For Consumers, Biotricity has its Biolife. This is a preventative care solution. It leverages the expertise gained from the Company’s Bioflux. The design of it is to help individuals track their progress in real-time so they can stay motivated to make lifestyle changes. Biolife helps users make lifestyle changes through uniting medically relevant ECG data with social media interactivity and a lifestyle log.

Bioflux comprises an ECG monitoring device, software, and access to a monitoring lab. The Bioflux software component is an acquisition that is already Food and Drug Administration (FDA) cleared. It is a standard for ECG monitoring in cardiac clinics and hospitals.

Biotricity has partnered with Global to Local (G2L). This collaboration between Biotricity and G2L will first center on building distinct solutions for outcome measurements for individuals suffering from chronic disease. G2L is an organization devoted to providing programs that improve individual and community health outcomes, expands access to healthcare services, and empowers economic development in the most varied and underserved communities.

Recently, Biotricity announced that the Company received its 510(k) clearance for its Bioflux device with the U.S. Food and Drug Administration (FDA). This latest 510(k) is the final FDA requirement required for Biotricity to bring to market Bioflux in the United States.

Biotricity commenced its first production run of the Bioflux solution. Large scale manufacturing is in place. Biotricity is set to start mass production.

Last week, Biotricity announced that it began extending the capabilities of its remote patient monitoring (RPM) platform with artificial intelligence (AI). This is to differentiate itself within the increasing remote monitoring marketplace. Biotricity is working with a proof of concept version of its RPM hardware with embedded AI.

The Company’s intention is that the initial commercial application be the next generation of its Bioflux device. It aims to file an additional 510(k) hardware clearance with the FDA by Q3 2018, prior to launching the next version.

Biotricity, Inc. (BTCY), closed Friday's trading session at $4.76, up 11.21%, on 81,184 volume with 196 trades. The average volume for the last 60 days is 163,713 and the stock's 52-week low/high is $1.81/$19.50.

GeoVax Labs, Inc. (GOVX)

Stock Stars, DrStockPick, HotOTC, Wall Street Resources, Stock News Now, SmallCapStockPlays, ProActive Capital, IRGnews Alert, PennyOmega, CoolPennyStocks, FeedBlitz, SmallCapVoice, M2 Communications, Standout Stocks, Stockpalooza, PennyTrader, Penny Performers, and Investor Place reported on GeoVax Labs, Inc. (GOVX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

GeoVax Labs, Inc. is a clinical-stage biotechnology company listed on the OTCQB. It is developing human vaccines against infectious diseases employing its MVA-VLP vaccine platform. The Company’s vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Established in 2001, GeoVax Labs is based in Smyrna, Georgia.

The Company’s development programs center on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, and also therapeutic vaccines for chronic Hepatitis B infections and cancers. Regarding VLPs, the production of VLPs in the person undergoing vaccination mimics a natural infection, stimulating the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear.

Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with financing from the National Institute of Allergy and Infectious Diseases (NIAID). All together, the Company’s HIV vaccines, in diverse doses and combinations, have been tested in 500 humans with very encouraging results.

In December, GeoVax Labs announced that it is collaborating with the U.S. Naval Research Laboratory (USNRL). This collaboration is to develop high-quality antibodies useful for detection of Lassa virus (LASV), and potentially as a treatment for Lassa Fever (LF). Lassa Fever is an acute viral hemorrhagic illness caused by LASV. A member of the Arenavirus family, LASV causes severe and often fatal hemorrhagic illnesses in West Africa.

Earlier this month, GeoVax Labs announced that it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. The foundation of GeoVax’s immuno-oncology program is on its Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform that produces non-infectious VLPs in the individual being vaccinated.

This collaboration between GeoVax Labs and Vaxeal Holding will include the design, construction, characterization and animal testing of vaccine candidates utilizing GeoVax’s MVA-VLP vaccine platform. Vaccine antigens will include Vaxeal’s proprietary designed sequences. Vaxeal Holding SA (Vevey, Switzerland), in partnership with foremost international research institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases.

Last week, GeoVax Labs announced the publication of its manuscript entitled “A Single-Dose of Modified Vaccinia Ankara Expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.” The paper is published in the peer-reviewed open access journal Scientific Reports by Nature Research.

The Company’s Ebola vaccine (GEO-EM01) is founded on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform. This platform produces noninfectious VLPs in the individual undergoing vaccination.

Farshad Guirakhoo, PhD, Chief Scientific Officer of GeoVax Labs, said, “GEO-EM01 uses GeoVax’s proven MVA-VLP vaccine platform that has been shown to be safe and to induce durable antibody and T-cell responses in multiple human clinical trials for GeoVax’s prophylactic HIV vaccine. Using the same platform, we have shown our Zika vaccine (GEO-ZM02) and our Lassa Fever vaccine (GEO-LM01) to provide single-dose 100 percent protection in mice against intracranial challenge."

GeoVax Labs, Inc. (GOVX), closed Friday's trading session at $0.0449, up 0.67%, on 608,512 volume with 33 trades. The average volume for the last 60 days is 1,435,701 and the stock's 52-week low/high is $0.0248/$0.1049.


The QualityStocks
Company Corner


Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.5725, off by 14.41%, on 332,676 volume with 150 trades. The stock’s average daily volume over the past 60 days is 81,323, and its 52-week low/high is $0.1265/$3.99.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Medical Innovation Holdings, Inc. (MIHI), a client of NNW that owns and operates strategically aligned health care service companies focused on the delivery of clinical virtual medicine (health) as a way of bringing quality medical care to all areas of need including rural and underdeveloped areas across the country. To view the full publication, titled “The Underlying Value of Cryptocurrencies,” visit: LINK

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

NetworkNewsWire Announces Publication on Healthcare Industry Seeking Security of Blockchain Technology

The Underlying Value of Cryptocurrencies

MIHI Initiates Development of Blockchain Platform for Health Care Records and Payments Systems

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.89, up 14.55%, on 827,903 volume with 1,168 trades. The stock’s average daily volume over the past 60 days is 515,109 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Enters Licensing Agreement with Canadian Cannabis Chocolate Manufacturer

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

AV1 Group, Inc. (AVOP)

The QualityStocks Daily Newsletter would like to spotlight AV1 Group, Inc. (AVOP). Today, AV1 Group, Inc. closed trading at $0.0348, up 17.97%, on 89,950 volume with 11 trades. The stock’s average daily volume over the past 60 days is 74,302 and its 52-week low/high is $0.017/$0.28.

AV1 Group, Inc. (AVOP), is a publicly traded investment and holding company established to identify, secure and monetize emerging growth companies in a number of sectors that include cannabis related technologies, grow houses and cultivation, and e-commerce businesses positioned for exponential growth. After identifying businesses displaying revolutionary concepts able to develop a substantial footprint in high-growth markets, the business model followed calls for incubating and supporting the best opportunities.

The company seeks to discover inspired entrepreneurs with innovative ideas that are poised for significant revenue generation. Management expertise can be seen in the development of embryonic-stage subsidiaries as the company brings a spectrum of backgrounds to the table with a significant resource of knowledge and experience to every venture. AV1 Group explores every opportunity to help each sector exceed its revenue goals while building close, active working relationships as it prepares each respective division to be a robust competitor within the various chosen markets.

AV1 Group companies include:

  • XFIRESmartSystems.com – Intelligent lighting solutions and wireless access for many different applications.
  • VaporHighUSA.com – Over 800 vaping products; bitcoin payments accepted.
  • DentalCannatizer.com – Revolutionary dual jet dental water jet integrates hemp oil infusing.
  • IntelligentLightingCorp.com – Comprehensive, energy-efficient lighting solutions.
  • CannaLighting.com – Wholly owned subsidiary building strategic relationships in the LED sector to provide solutions for grow houses and cultivation centers.
  • MJIQ – First, comprehensive, enterprise-grade integrated software suite being developed for the legal cannabis industry.
  • Hemptory.com – Engaging online destination for all hemp and cannabis related products and services.
  • Lawster.com – Puts consumers and small businesses in contact with legal services and service providers.
  • MJTestLabs.com – Under development website will serve cannabis dispensaries, laboratories and industry affiliates.

AV1 Group's business model delivers an advantage with internally-created projects that are poised for revenue generation and a cross-company revenue platform that enables the company to incubate and foster growth in early-stage subsidiaries under one umbrella. Disclaimer

AV1 Group, Inc. Blog

AV1 Group, Inc. News:

NetworkNewsWire Announces Publication Featuring Growth Opportunities for Innovators of Lighting Technologies

AV1 Group Announces Purchase Order from an Additional California Prison

AV1 Group, Inc. (AVOP) Engages NetworkNewsWire for Corporate Communications Solutions

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0028, up 40.00%, on 20,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 151,892, and its 52-week low/high is $0.0005/$0.008.

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company's commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ ("UMI") solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company's UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum's wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company's UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI's technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum's primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum's management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum's management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings, Inc. to Release Wild Spots Bingo Mobile App in European Countries

Consorteum Holdings, Inc. Extends Strategic Agreement with Knockout Gaming

Consorteum Holdings, Inc. Completes Framework Integration of its Universal Mobile Interface(TM) ("UMI")

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $1.09, up 10.18%, on 1,085,332 volume with 822 trades. The stock’s average daily volume over the past 60 days is 1,833,086, and its 52-week low/high is $0.177/$1.95.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Closes Over-Subscribed C$9.4 Million Financing

CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis

CannabisNewsWire Announces Publication on Influx of Capital Ahead of Expanded Cannabis Legalization in North America

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.47, up 8.05%, on 105,687 volume with 48 trades. The stock’s average daily volume over the past 60 days is 1,936, and its 52-week low/high is $0.01/$0.70.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

Fast-Growing Cannabis Industry Drives Biotech Research, Innovative Medical Therapy Development

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is “One to Watch”

PreveCeutical Announces Amendment to $3.28 Million Non-Brokered Private Placement

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.024, off by 4.00%, on 447,544 volume with 16 trades. The stock’s average daily volume over the past 60 days is 230,326 and its 52-week low/high is $0.02/$0.33.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible Announces Proposed Merger with Quoin Pharmaceuticals

New Skinvisible, Inc. (SKVI) Subsidiary Signs Exclusive License Agreement to Distribute Its Topical Cannabis Products in the USA

Skinvisible, Inc. (SKVI) Engages NetworkNewsWire for Corporate Communications Solutions


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Planet Penny Stocks
(HMPQ) +143.75%


(CSRH) +40.00%


(BSPM) +35.51%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251